New antibiogram!

/

The GLA antibiogram for calendar year 2022 is here!  Head on over to the “Susceptibilities” tab to check it out. Some highlights:

 

For Gram-negative rods in the hospital setting:

 

  • Carbapenem-resistant Enterobacterales remain relatively uncommon at GLA, but extended-spectrum beta-lactamase-producing Gram-negative rods are common in the nosocomial setting (example: 57% and 49% ceftriaxone susceptibility among nosocomial urinary and non-urinary E. coli, respectively).

 

  • Amikacin remains most active agent vs. multi-drug resistant Gram-negative rod infections at GLA.

 

  • If specific coverage for Pseudomonas is warranted, susceptibilities slightly favor piperacillin-tazobactam over cefepime and meropenem, though meropenem and ertapenem have better coverage against non-Pseudomonas Gram-negative nosocomial isolates.

 

  • Fluoroquinolone susceptibility versus most nosocomial Gram-negative organisms remains relatively poor.

 

For Gram-negative rods in the outpatient setting:

 

  • Cefazolin susceptibility among common urinary Enterobacterales is not readily captured but susceptibility rates among other beta-lactams remain relatively stable

 

  • Fluoroquinolone and TMP-SMX susceptibilities remain largely stable

 

Key trends among Gram-positive isolates:

 

  • MRSA 53% of nosocomial non-blood isolates, 76% of nosocomial blood isolates

 

  • MRSA ~40% outpatient non-blood isolates

 

  • Doxycycline susceptibility remains stable among non-blood outpatient S. aureus isolates (88%)